- Report
- December 2024
- 55 Pages
Global
From €2274EUR$2,499USD£1,950GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- April 2025
- 175 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- August 2022
- 214 Pages
Global
From €4368EUR$4,799USD£3,744GBP
- Report
- October 2023
- 183 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Book
- December 2020
Global
- Book
- September 2024
North America
- Book
- October 2023
North America
- Book
- July 2021
North America
- Book
- June 2019
North America

The B Cell market within the context of Oncology is a rapidly growing field of research and development. B Cells are a type of white blood cell that play a key role in the body's immune system. In oncology, B Cells are used to target and destroy cancer cells. B Cell therapies are a type of immunotherapy, which is a form of cancer treatment that uses the body's own immune system to fight the disease. B Cell therapies are being developed to target a variety of cancers, including lymphoma, leukemia, and multiple myeloma.
B Cell therapies are being developed by a number of companies, including Kite Pharma, Juno Therapeutics, and Bluebird Bio. These companies are working to develop treatments that are more effective and have fewer side effects than traditional chemotherapy and radiation treatments. Additionally, these companies are researching ways to use B Cells to target and destroy cancer cells without damaging healthy cells. Show Less Read more